RecruitingNot ApplicableNCT06890312

Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)


Sponsor

University Hospital, Strasbourg, France

Enrollment

550 participants

Start Date

Jun 5, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers. However, data on the effect of the timing of heparin injection are limited. The investigators hypothesize that injection of heparin before sheath insertion may reduce the rate of radial artery occlusion compared with injection after sheath insertion.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention
  • Subject affiliated to a social protection health insurance
  • Subject able to understand the objectives and risks of the research and to provide dated and signed consent
  • Subject who has been informed of the results of the preliminary medical examination

Exclusion Criteria9

  • Contraindication to the use of heparin (history of heparin-induced thrombocytopenia)
  • Very high bleeding risk defined by recent bleeding (\<6 months) of type 3 of the BARC classification
  • Subject in an exclusion period (determined by a previous or ongoing study)
  • Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.)
  • Subject under safeguard of justice
  • Subject under guardianship or curatorship
  • Pregnancy
  • Breastfeeding
  • Patient on anticoagulant treatment: anti-vitamin K, direct oral anticoagulants (DOACs).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREAdministration of heparin after sheath insertion

Administration of heparin after sheath insertion

PROCEDUREAdministration of heparin prior to sheath insertion

Administration of heparin prior to sheath insertion


Locations(1)

Hôpitaux Universitaires de Strasbourg

Strasbourg, Bas-Rhin, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06890312


Related Trials